(Sharecast News) - Merck and Moderna surged on Wednesday after the pharmaceutical companies said a personalised mRNA melanoma vaccine they are jointly developing showed positive results in a first-ever late-stage trial.
The company hailed positive topline results from the Phase 3 trial of intismeran, a novel investigational mRNA-based individualised neoantigen therapy...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE